HCA Holdings Inc (NYSE:HCA) announced that certain of its stockholders, consisting principally of affiliates of, or funds sponsored by, Bain Capital Partners, LLC and Kohlberg Kravis Roberts & Co. (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering 15 million shares of its common stock pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission.HCA Holdings Inc (NYSE:HCA) net profit margin is 4.50% and weekly performance is -1.22%. On last trading day company shares ended up $51.72. Analysts mean target price for the company is $58.45. HCA Holdings Inc (NYSE:HCA) distance from 50-day simple moving average (SMA50) is 2.45%.
Bristol-Myers Squibb Co (NYSE:BMY) is one of the companies pushing the Drugs industry. Thus far, 2.8 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.7 million shares. Bristol-Myers Squibb Co (NYSE:BMY) shares fell -1.18% in last trading session and ended the day on $48.76. BMY Gross Margin is 72.40% and its return on assets is 8.00%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly performance is -8.16%.
On 19 MAY Pfizer Inc. (NYSE:PFE) announced a possible offer comprising, for each AstraZeneca share, 1.747 shares in the combined entity and 2,476 pence in cash, representing an indicative value of £55.00.Pfizer Inc. (NYSE:PFE) shares moved down -0.10% in last trading session and was closed at $29.25, while trading in range of $29.21 – $29.54. Pfizer Inc. (NYSE:PFE) year to date (YTD) performance is -2.86%.
MannKind Corporation (NASDAQ:MNKD) VP Diane Palumbo unloaded 18,176 shares of MannKind stock on the open market in a transaction dated Thursday, May 15th. The shares were sold at an average price of $7.06, for a total transaction of $128,322.56.MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $7.57. Company weekly volatility is calculated as 6.22% and price to cash ratio as 82.17. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 15.05%.
On 19 MAY Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported a net loss per share of 12 cents in the Q1 of 2014. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had incurred a narrower loss of 9 cents in the year-ago quarter. Arena Pharma recorded Q1 revenues of $2.9 million benefiting from revenues recorded for its obesity drug, Belviq.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) net profit margin is -30.20% and weekly performance is -1.25%. On last trading day company shares ended up $6.33. Analysts mean target price for the company is $7.83. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is -1.81%.